Loading…
Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. It also sells and rents HME devices, such as non-invasive and invasive ventilators, positive airway pressure (PAP) machines, durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment. In addition, the company provides neuromuscular care and oxygen therapy services; and sleep apnea management which provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, it offers in-home sleep apnea testing services; and breast pumps and related lactation equipment and supplies, including fulfillment and support services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $270M | $52M | $15M | $12M | 10.6% | 20.5% | 32.6% |
| 2024 | $224M | $42M | $11M | $1M | 8.6% | 22.5% | 10.0% |
| 2023 | $183M | $37M | $10M | $19M | 9.0% | 31.8% | 64.6% |
| 2022 | $139M | $25M | $6M | $5M | 6.4% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 138.83 | 183.01 | 224.26 | 270.28 |
| Operating Revenue | - | 138.83 | 183.01 | 224.26 | 270.28 |
| Cost Of Revenue | - | 54.15 | 70.22 | 91.05 | 114.82 |
| Gross Profit | - | 84.68 | 112.78 | 133.20 | 155.46 |
| Operating Expense | - | 76.08 | 97.81 | 117.21 | 134.75 |
| Research And Development | - | 2.70 | 2.78 | 3.07 | 3.02 |
| Selling General And Administration | - | 73.36 | 93.73 | 112.48 | 130.50 |
| Total Expenses | - | 130.23 | 168.03 | 208.26 | 249.57 |
| Operating Income | - | 8.60 | 14.98 | 16 | 20.71 |
| Total Operating Income As Reported | - | 8.25 | 14.33 | 17.90 | 22.95 |
| EBITDA | - | 24.82 | 36.68 | 42.31 | 51.56 |
| Normalized EBITDA | - | 25.16 | 36.84 | 41.36 | 49.32 |
| EBIT | - | 9.19 | 14.82 | 16.95 | 22.95 |
| Interest Expense | - | 0.20 | 0.42 | 0.78 | 1.18 |
| Net Interest Income | - | -0.20 | -0.42 | -0.78 | -1.18 |
| Other Income Expense | - | 0.59 | -0.16 | 0.95 | 2.24 |
| Interest Expense Non Operating | - | 0.20 | 0.42 | 0.78 | 1.18 |
| Net Non Operating Interest Income Expense | - | -0.20 | -0.42 | -0.78 | -1.18 |
| Pretax Income | - | 8.99 | 14.39 | 16.17 | 21.77 |
| Tax Provision | - | 2.77 | 4.15 | 4.76 | 6.39 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.11 | -0.05 | 0.28 | 0.66 |
| Net Income Continuous Operations | - | 6.22 | 10.24 | 11.41 | 15.38 |
| Net Income From Continuing And Discontinued Operation | - | 6.22 | 10.24 | 11.26 | 14.93 |
| Net Income From Continuing Operation Net Minority Interest | - | 6.22 | 10.24 | 11.26 | 14.93 |
| Net Income | - | 6.22 | 10.24 | 11.26 | 14.93 |
| Net Income Common Stockholders | - | 6.22 | 10.24 | 11.26 | 14.93 |
| Net Income Including Noncontrolling Interests | - | 6.22 | 10.24 | 11.41 | 15.38 |
| Normalized Income | - | 6.46 | 10.36 | 10.59 | 13.35 |
| Diluted NI Availto Com Stockholders | - | 6.22 | 10.24 | 11.26 | 14.93 |
| Basic Average Shares | 39.49 | 38.66 | 38.35 | 38.75 | - |
| Diluted Average Shares | 40.68 | 39.81 | 40.38 | 40.81 | - |
| Reconciled Depreciation | - | 15.63 | 21.86 | 25.37 | 28.61 |
| Reconciled Cost Of Revenue | - | 39.53 | 49.75 | 67.17 | 87.69 |
| Total Unusual Items | - | -0.35 | -0.16 | 0.95 | 2.24 |
| Total Unusual Items Excluding Goodwill | - | -0.35 | -0.16 | 0.95 | 2.24 |
| Minority Interests | - | 0 | 0 | -0.14 | -0.44 |
| Special Income Charges | - | -0.35 | -0.64 | 1.90 | 2.24 |
| Gain On Sale Of Security | - | - | 0.48 | -0.95 | - |
| Depreciation Amortization Depletion Income Statement | - | 1.01 | 1.39 | 1.48 | 1.48 |
| Depreciation And Amortization In Income Statement | - | 1.01 | 1.39 | 1.48 | 1.48 |
| General And Administrative Expense | - | 73.36 | 93.73 | 112.48 | 130.50 |
| Other Gand A | - | 68.16 | 87.88 | 106.20 | 121.37 |
| Salaries And Wages | - | 5.20 | 5.85 | 6.28 | 9.13 |
| Gain On Sale Of Ppe | - | -0.35 | -0.64 | 1.90 | 2.24 |
| Total Other Finance Cost | 0.32 | - | - | - | - |
| Other Operating Expenses | - | -0.99 | -0.10 | 0.17 | -0.25 |
| Earnings From Equity Interest | 1.24 | 0.94 | 0.48 | -0.95 | - |
| Depreciation Income Statement | 0.85 | 1.01 | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Viemed Healthcare, Inc.this co. | VMD | $377M | 25.26 | 2.67 | 10.6% | 7.36 |
| OmniAb, Inc. | OABI | $386M | -5.95 | 1.44 | -24.3% | -8.06 |
| Compass Therapeutics, Inc. | CMPX | $384M | -5.77 | 1.95 | -33.8% | -5.08 |
| Benitec Biopharma Inc. | BNTC | $380M | -10.01 | 3.90 | -39.0% | -6.83 |
| CapsoVision, Inc. | CV | $377M | -14.88 |
| - |
| - |
| - |
| - |
| - |
| 28.41 |
| -190.9% |
| -14.73 |
| Vanda Pharmaceuticals Inc. | VNDA | $376M | - | 1.15 | -67.4% | - |
| Lexeo Therapeutics, Inc. | LXEO | $375M | -3.75 | 1.52 | -40.5% | -3.28 |
| Delcath Systems, Inc. | DCTH | $372M | 137.96 | 3.35 | 2.4% | 327.03 |
| Perspective Therapeutics, Inc. | CATX | $371M | -3.59 | 1.79 | -49.8% | -3.41 |
| Peer Median | - | -5.77 | 1.87 | -39.7% | -5.08 | |